STEWART H LECKER, M.D.
Osteopathic Medicine at Brookline Ave, Boston, MA

2003007, Apr 24, 2003

Jan 16, 2002

10/050686

Alfred Goldberg - Chestnut Hill MA, US
Marcelo Gomes - Brookline MA, US
Stewart Lecker - Brookline MA, US
R. Jagoe - Ellesmere, GB

A61K038/43, C07K014/435

424/185100, 424/094100, 530/350000

The present invention relates to the isolation of cell- or tissue-specific F-box proteins which are involved in ubiquitin-mediated protein degradation in a specific cell- or tissue-type. Accordingly, the invention provides nucleic acids and the proteins encoded by said nucleic acids which play a role in the ubiquitinylation and subsequent degradation of substrate proteins and in regulating cell proliferation, cell differentiation, and cell survival. The invention also provides methods for modulating protein degradation, cell proliferation, cell differentiation and/or cell survival by modulating protein ubiquitination; assays for identifying compounds which modulate protein degradation, cell proliferation, differentiation and/or cell survival; methods for treating disorders associated with aberrant protein degradation, cell proliferation, cell differentiation, and/or cell survival; and diagnostic and prognostic assays for determining whether a subject is at risk of developing a disorder associated with an aberrant protein degradation, cell proliferation, cell differentiation, and/or survival.

2010031, Dec 9, 2010

Jun 5, 2008

12/663423

Vikas P. Sukhatme - Newton MA, US
Stewart H. Lecker - Brookline MA, US
Junichi Hanai - Boston MA, US

Beth Israel Deaconess Medical Center - Boston MA

A61K 39/395, A61K 38/02, A61K 31/675, A61K 31/7105, G01N 33/68, C12Q 1/68, G01N 33/566, G01N 33/53, C12N 5/07, A61P 21/00

4241581, 514 11, 514 81, 514 44 A, 435 71, 435 6, 436501, 436 86, 436 94, 435375

The invention provides compositions and kits containing an atrogin-1 inhibitor compound useful for the treatment of a statin-mediated myopathy. Kits for the diagnosis of a statin-mediated myopathy are also provided. The invention further features methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of an atrogin-1 inhibitor compound. The invention further provides methods of diagnosing a subject as having a propensity to develop a statin-induced myopathy and methods of monitoring a statin-induced myopathy or a propensity to develop a statin-mediated myopathy in a subject. The invention also features methods for identifying a compound for the treatment of a statin-mediated myopathy and methods of identifying a statin compound as having the propensity to induce a statin-mediated myopathy.

2012017, Jul 5, 2012

Apr 27, 2010

13/266355

Vikas P. Sukhatme - Newton MA, US
Stewart H. Lecker - Brookline MA, US
Jun-ichi Hanai - Boston MA, US

Beth Isreal Deaconess Medical Center - Boston MA

A61K 9/20, A61K 31/19, A61K 31/66, A61K 31/366

424464, 514460, 514557, 514106

Disclosed are methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of a geranylgeranylation activator. Further disclosed are kits containing a geranylgeranylation activator useful for the treatment of a statin-mediated myopathy.

2006006, Mar 30, 2006

Dec 28, 2004

11/024371

Alfred Goldberg - Chestnut Hill MA, US
Stewart Lecker - Brookline MA, US
Marco Sandri - Boston MA, US

President and Fellows of Harvard College - Cambridge MA

A61K 48/00, C12Q 1/68

514044000, 435006000

The present invention relates to regulating the activity of Foxo and prevention and treatment of diseases associated with aberrant Foxo activity.